Chuck Miller - Mersana Therapeutics Senior Affairs
| MRSN Stock | USD 2.04 0.06 3.03% |
Executive
Chuck Miller is Senior Affairs of Mersana Therapeutics
| Address | 840 Memorial Drive, Cambridge, MA, United States, 02139 |
| Phone | 617 498 0020 |
| Web | https://www.mersana.com |
Mersana Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.263) % which means that it has lost $0.263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1333) %, meaning that it created substantial loss on money invested by shareholders. Mersana Therapeutics' management efficiency ratios could be used to measure how well Mersana Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.8. In addition to that, Return On Capital Employed is likely to drop to -1.11. At this time, Mersana Therapeutics' Other Current Assets are very stable compared to the past year. As of the 22nd of November 2024, Fixed Asset Turnover is likely to grow to 5.34, while Total Assets are likely to drop about 180.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Soojin Kim | Inozyme Pharma | N/A | |
| Catherine MD | Syndax Pharmaceuticals | 52 | |
| Joseph MD | Syndax Pharmaceuticals | N/A | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Deborah Palestrant | Relay Therapeutics | N/A | |
| Pamela Esposito | Replimune Group | 50 | |
| Helen Milton | Viridian Therapeutics | N/A | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Carolyn JD | Arcus Biosciences | 45 | |
| Shannon Campbell | Merus BV | 58 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Eric Hoefer | Arcus Biosciences | N/A | |
| Carena Spivey | Protagonist Therapeutics | N/A | |
| Shan Wu | Viridian Therapeutics | N/A | |
| Seth Harmon | Viridian Therapeutics | 44 | |
| Christopher Keenan | Pliant Therapeutics | N/A | |
| Eric MD | Pliant Therapeutics | 60 | |
| Melissa Manno | Viridian Therapeutics | N/A | |
| Andrew Schwendenman | Replimune Group | 48 | |
Management Performance
| Return On Equity | -2.13 | ||||
| Return On Asset | -0.26 |
Mersana Therapeutics Leadership Team
Elected by the shareholders, the Mersana Therapeutics' board of directors comprises two types of representatives: Mersana Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mersana. The board's role is to monitor Mersana Therapeutics' management team and ensure that shareholders' interests are well served. Mersana Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mersana Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chuck Miller, Senior Affairs | ||
| Carla Poulson, Chief Officer | ||
| Marc Damelin, Oncology, Biology | ||
| Martin MD, CEO President | ||
| Jason Fredette, Senior Communications | ||
| Ashish Mandelia, Vice President Controller | ||
| Mohan Bala, Senior Officer | ||
| Tushar Misra, Senior Officer | ||
| Timothy Lowinger, Chief Scientific Officer | ||
| MD Huber, CEO President | ||
| Anna MBA, CEO Pres | ||
| Alejandra JD, Secretary SVP | ||
| Brian DeSchuytner, Senior Vice President - Finance and Product Strategy | ||
| Mikhail Papisov, CoFounder |
Mersana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mersana Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.13 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.14) % | ||||
| Operating Margin | (0.96) % | ||||
| Current Valuation | 120.93 M | ||||
| Shares Outstanding | 123.53 M | ||||
| Shares Owned By Insiders | 1.25 % | ||||
| Shares Owned By Institutions | 95.35 % | ||||
| Number Of Shares Shorted | 9.87 M | ||||
| Price To Earning | (0.98) X |
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Mersana Stock
| 0.82 | VALN | Valneva SE ADR | PairCorr |
| 0.71 | BACK | IMAC Holdings | PairCorr |
| 0.69 | AGL | agilon health | PairCorr |
| 0.64 | MTEM | Molecular Templates | PairCorr |
| 0.63 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Revenue Per Share 0.286 | Quarterly Revenue Growth 0.637 | Return On Assets (0.26) | Return On Equity (2.13) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.